A phase 1 study of oral LOXO 292 in adult patients with advanced solid tumors, including RET-fusion non-small cell lung cancer, medullary thyroid cancer and other tumors with increased RET activity
Keyword(s):
Phase 1
◽
Keyword(s):
Keyword(s):
2015 ◽
Vol 93
(3)
◽
pp. S86
◽